FINWIRES · TerminalLIVE
FINWIRES

Hyatt Hotels Analyst Day Reinforces Confidence in Growth, Capital Returns, Morgan Stanley Says

By

Hyatt Hotels' (H) analyst day boosted confidence in its long-term growth outlook, with increased buybacks helping offset concerns about room growth visibility, Morgan Stanley said in a note Monday.

The bank said the event largely reinforced its positive view of the company and increased its confidence that Hyatt can sustain a premium growth profile while returning capital to shareholders at levels similar to higher-valued peers.

Investors may continue to question the visibility of future room growth due to Hyatt's conversion-heavy strategy, and remain concerned about the complexity of its distribution business and the balance between buybacks and mergers and acquisitions, the firm said.

The bank added that it sees upside from co-brand credit card fees as well as management's shift in tone toward repurchase as offsetting these concerns.

Looking further ahead, Hyatt's long-term growth potential remains "undeniable," the firm said, adding that the company has lower market penetration than many peers, but has continued its outperformance in revenue per available room and gross operating profit per available room.

Morgan Stanley raised its price target on Hyatt Hotels from $195 to $208 while keeping its overweight rating.

Price: $182.23, Change: $+0.87, Percent Change: +0.48%

Related Articles

Wire

Monster Beverage Set for Margin Rebound in 2027, Morgan Stanley Says

Monster Beverage (MNST) is positioned for margin improvement in 2027 and beyond as it works through aluminum and geographic-mix pressure and benefits from several structural tailwinds, Morgan Stanley said Sunday in a report.Q1 results showed solid regional gross margins, better-than-expected aluminum cost management, and stronger underlying corporate gross margins after adjusting for negative geographic mix, the report said.The company also has several drivers of margin expansion, including increased pricing power, favorable product mix, and better cost leverage, Morgan Stanley said. Monster's potential divestiture of its alcohol business would also be accretive to margins and earnings, the report said.Morgan Stanley raised its price target on Monster stock to $103 from $100 and reiterated its overweight rating.Price: $89.00, Change: $+0.92, Percent Change: +1.04%

$MNST
Wire

Methanex Seen Benefiting From Elevated Methanol Pricing Despite Expected Normalization, RBC Says

Methanex (MEOH) is expected to benefit from a still-elevated methanol pricing environment even as prices gradually normalize over the medium term, according to updated industry forecasts and ongoing supply-side disruptions, RBC Capital said in a Friday note.Commodity Market Analytics raised its methanol price outlook through 2028, with the largest upward revisions in 2027 due to supply constraints in the Middle East and logistical disruptions such as the Strait of Hormuz, while prices are still expected to gradually ease from late 2026 but remain above pre-disruption levels, according to the report.RBC noted that Methanex's near-term reference prices are expected to remain stable across North America, China, and Asia Pacific, with elevated pricing supporting strong free cash flow generation and 2026 prices likely staying well above historical averages, aiding deleveraging efforts.The analyst said Methanex's earnings are highly sensitive to methanol price changes, which significantly impact adjusted EBITDA, and added that the company has potential capital allocation flexibility, including continued debt reduction and possible share buybacks starting in late 2026.RBC maintained its sector perform rating on the stock with a price target of $70.Methanex shares were up 2% in Monday trading.Price: $60.28, Change: $+1.18, Percent Change: +2.00%

$MEOH
Wire

Ensign Group's Regulatory, Reimbursement Concerns 'Overblown,' Oppenheimer Says

Ensign Group's (ENSG) recent stock price drop presents a buying opportunity, as regulatory and reimbursement concerns are "overblown," Oppenheimer said in a note Monday.With the company maintaining its strong operational performance, it should be able to handle volatility in managed care admissions and referrals, which represent about 14% of patient days and 20% of revenue, Oppenheimer analysts said.Ensign's occupancy percentage has risen to 84.3% but remains below its competitors'. The difference can be partially explained by market-related factors, and presents a long-term upside for the company, the analysts said.Oppenheimer also pointed to Ensign's acquisition pipeline as a driver of growth, noting that the company has added 71 locations since the start of 2025 and continues to see a healthy pipeline of merger and acquisition opportunities.Ensign's strategy of acquiring underperforming assets and unlocking operational upside from those facilities has helped it outperform in the historically challenging skilled nursing facility operating and reimbursement environment, according to the note.Oppenheimer maintained the company's stock rating at outperform, with a price target of $210.Price: $165.20, Change: $-2.46, Percent Change: -1.46%

$ENSG